New Nordic Healthbrands AB Logo

New Nordic Healthbrands AB

Develops and markets herbal supplements & beauty products for natural wellness consumers globally.

NNH | ST

Overview

Corporate Details

ISIN(s):
SE0001838038
LEI:
213800JGTLNSKRD49G44
Country:
Sweden
Address:
SÖDRA FÖRSTADSGATAN 3, 211 43 MALMÖ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

New Nordic Healthbrands AB is a company specializing in the development, marketing, and sale of herbal-based dietary supplements, natural remedies, and beauty products. Since its establishment in 1990, the company has focused on leveraging its expertise in medicinal plants to create innovative products that address specific health and beauty needs. New Nordic emphasizes scientific validation and quality control, analyzing all ingredients in controlled laboratories to ensure the safety and effectiveness of its offerings. The company markets its distinct brands globally to consumers seeking natural wellness solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all New Nordic Healthbrands AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for New Nordic Healthbrands AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for New Nordic Healthbrands AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 Karl Kristian Bergman Jensen Other Sell 5,000 115,000.00 SEK
2025-03-12 Karl Kristian Bergman Jensen Other Sell 5,000 74,900.00 SEK
2025-03-11 Karl Kristian Bergman Jensen Other Sell 5,000 79,500.00 SEK
2025-03-05 Karl Kristian Bergman Jensen Other Sell 5,000 81,250.00 SEK
2025-01-22 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2025-01-21 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2025-01-20 Karl Kristian Bergman Jensen Other Sell 5,000 73,500.00 SEK
2024-12-27 Karl Kristian Bergman Jensen Other Sell 5,000 74,050.00 SEK
2024-12-18 Karl Kristian Bergman Jensen Other Sell 5,000 73,300.00 SEK
2024-09-06 Karl Kristian Bergman Jensen Other Sell 4,000 61,960.00 SEK

Peer Companies

Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950

Talk to a Data Expert

Have a question? We'll get back to you promptly.